ReferenceID 2108
Irigenin inhibits glioblastoma progression through suppressing YAP/β-catenin signaling
Front Pharmacol
Glioblastoma (GBM) is the most malignant glioma in brain tumors with low survival and high recurrence rate. Irigenin, as an isoflavone compound extracted from Shegan, has shown many pharmacological functions such as anti
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 2108
- Evidence Id
- 18698
- Core Evidence Id
- 18698
- Source Reference Id
- 4241
- Herb2 Reference Id
- HBREF005038
- Subject Paper Key
- HBIN030301_36532767
- Pubmed Id
- 36532767
- Doi
- 10.3389/fphar.2022.1027577
- Paper Title
- Irigenin inhibits glioblastoma progression through suppressing YAP/β-catenin signaling
- Paper Abstract
- Glioblastoma (GBM) is the most malignant glioma in brain tumors with low survival and high recurrence rate. Irigenin, as an isoflavone compound extracted from Shegan, has shown many pharmacological functions such as antioxidant, anti-inflammatory and anti-tumor. However, the effects of irigenin on GBM cells and the related molecular mechanisms remain unexplored. In this study, we found that irigenin inhibited the proliferation of GBM cells in a dose-dependent manner by several assays in vitro . Subsequently, we found that irigenin arrested cell cycle at G2/M phase and induced apoptosis of GBM cells in vitro . In addition, irigenin inhibited the migration of GBM cells. Mechanically, we found that irigenin treatment decreased the expression of YAP (yes-associated protein), suppressed β-catenin signaling. Furthermore, overexpression of YAP partially restored the anti-tumor effects of irigenin on GBM cells in vitro . Finally, we found that irigenin inhibited the growth of tumor in GBM xenograft mice model through inactivation of YAP. Taken together, these results suggest that irigenin exerts its anticancer effects on GBM via inhibiting YAP/β-catenin signaling, which may provide a new strategy for the treatment of GBM.
- Journal
- Front Pharmacol
- Publish Year
- 2022
- Experiment Subject
- mouse
- Experiment Type
- Cell Experiment
- Phenotype Related
- Malignant Glioma; Brain Tumors; Tumor; Glioblastoma
- Paper Title Cn
- Paper Title En
- Irigenin inhibits glioblastoma progression through suppressing YAP/β-catenin signaling
- Bilingual Status
- semi_complete